Path ID: DB11921_MESH_D020388_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:C021988 | deflazacort | Drug |
| DB:DBMET02573 | 21-deflazacort | ChemicalSubstance |
| UniProt:P04150 | Glucocorticoid receptor | Protein |
| GO:0006954 | inflammatory response | BiologicalProcess |
| HP:0003323 | Progressive muscle weakness | PhenotypicFeature |
| MESH:D020388 | Duchenne muscular dystrophy | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Deflazacort | HAS METABOLITE | 21-Deflazacort |
| 21-Deflazacort | POSITIVELY REGULATES | Glucocorticoid Receptor |
| Glucocorticoid Receptor | NEGATIVELY REGULATES | Inflammatory Response |
| Inflammatory Response | CORRELATED WITH | Progressive Muscle Weakness |
| Progressive Muscle Weakness | MANIFESTATION OF | Duchenne Muscular Dystrophy |
Comment: The exact mechanism by which deflazacort exerts its therapeutic effects in patients with DMD is unknown but likely occurs via its anti-inflammatory activities.
Reference: